Table 5.
Clinical trials on adjuvant chemotherapy for pancreatic cancer
| Author | Year | Study | Design | n | mDFS, mo | P | MST, mo | P |
|---|---|---|---|---|---|---|---|---|
| Oettle 132 | 2013 | CONKO‐001 | GEM vs Surgery | 354 | 13.4 vs 6.7 | <.001 | 22.8 vs 20.2 | .06 |
| Neptolemos 134 | 2010 | ESPAC‐3 | 5‐FU/FA vs Surgery | 458 | ‐ | ‐ | 23.2 vs 16.8 | .003 |
| Uesaka 135 | 2016 | JASPAC01 | S‐1 vs GEM | 385 | 22.9 vs 11.3 | <.0001 | 46.5 vs 25.5 | <.0001 |
| Neptolemos 136 | 2017 | ESPAC‐4 | GEM + Cap vs GEM | 730 | 13.9 vs 13.1 | .082 | 28.0 vs 25.5 | .032 |
| Sinn 137 | 2017 | CONKO‐005 | GEM + Erulotinib vs GEM | 436 | 11.4 vs 11.4 | .26 | 24.5 vs 26.5 | .61 |
| Conroy 138 | 2018 | PRODIGE 24/CCTG PA.6 | FOLFIRINOX vs GEM | 493 | 21.0 vs 12.8 | <.001 | 54.4 vs 35.0 | .003 |
Abbreviations: Cap, capecitabine; FA, folinic acid; FOLFIRINOX, levofolinate + 5‐FU + irinotecan+oxaliplatin; GEM, gemcitabine; mDFS, median disease‐free survival; mo, months; MST, median overall survival.